Phase III clinical trial - Sein métastatique HER2+

SOPHIA (CP-MGAH22-04)
Sein métastatique HER2+
Essai clinique fermé
Public cible
Adulte
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
Description de l'essai

The purpose of this study is to determine whether patients treated with margetuximab plus chemotherapy have longer progression free survival and overall survival than patients treated with trastuzumab plus chemotherapy